Clinical bottom line
Early initiation of novel oral cardiac myosin inhibitors in patients with cardiac amyloidosis represents a promising therapeutic avenue that may improve patient-reported symptoms and potentially modify disease progression. Emerging evidence suggests these agents could reduce myocardial contractile stress and fibrosis, thereby improving functional status. However, current data remain preliminary and largely hypothesis-generating, underscoring the need for rigorous prospective studies to clarify their impact on long-term clinical outcomes in this population.
What the evidence shows
Cardiac amyloidosis, characterized by extracellular amyloid deposition leading to restrictive cardiomyopathy, remains a challenging condition with limited disease-modifying therapies. Novel oral myosin inhibitors, initially developed for obstructive hypertrophic cardiomyopathy, have been investigated for their potential to reduce myocardial hypercontractility and fibrosis, mechanisms also relevant in amyloid cardiomyopathy.
O’Hara et al. (2026) examined patient-reported outcomes following initiation of myosin inhibitors in cardiac amyloidosis, finding that symptom burden, particularly dyspnea and fatigue, improved in the early treatment phase. This suggests a favorable impact on functional status, although the study was observational and limited by short follow-up.
Lu et al. (2026) conducted a meta-analysis of cardiac magnetic resonance imaging outcomes in patients treated with cardiac myosin inhibitors, demonstrating reductions in myocardial fibrosis and favorable remodeling in hypertrophic cardiomyopathy. While this meta-analysis did not specifically include amyloidosis cohorts, the pathophysiologic overlap supports a putative benefit in amyloid cardiomyopathy, warranting further validation.
Complementary to this, Kuehn et al. (2023) emphasized the critical importance of early diagnosis and treatment initiation in cardiac amyloidosis to improve survival and functional outcomes. This aligns with the hypothesis that early myosin inhibitor therapy could attenuate disease progression if started before advanced myocardial damage occurs.
Notably, other pharmacologic classes such as SGLT2 inhibitors have shown promise in cardiac amyloidosis. Nwaezeapu et al. (2026) and Sivamurugan et al. (2024, 2025) reported reductions in arrhythmia burden and improved cardiac outcomes with SGLT2 inhibitors in transthyretin cardiac amyloidosis, highlighting the evolving therapeutic landscape and the need to delineate the role of myosin inhibitors within it.
Caveats and uncertainty
The current evidence base for myosin inhibitors in cardiac amyloidosis is limited by small sample sizes, observational designs, and extrapolation from related cardiomyopathies rather than amyloidosis-specific randomized controlled trials. The heterogeneity of amyloidosis subtypes (e.g., AL vs. transthyretin) and disease stages complicates generalizability.
Moreover, the long-term safety profile of myosin inhibitors in this population remains incompletely characterized, particularly regarding potential negative inotropic effects or interactions with amyloid-specific therapies. The impact on hard clinical endpoints such as mortality, hospitalization, and arrhythmia incidence is not yet established.
Finally, the interplay between myosin inhibitors and other emerging treatments, including SGLT2 inhibitors and transthyretin stabilizers, requires careful evaluation to optimize combination strategies.
How this may change practice
Pending further validation, early initiation of oral myosin inhibitors could become an adjunctive strategy in managing cardiac amyloidosis, particularly for patients with symptomatic heart failure and evidence of myocardial fibrosis. Clinicians should remain vigilant for evolving evidence and consider multidisciplinary evaluation including amyloidosis specialists when contemplating these agents.
Integration of advanced imaging and biomarker assessment may help identify candidates most likely to benefit from early myosin inhibition. Additionally, coordination with amyloid-specific therapies and arrhythmia management will be essential to optimize outcomes.
Ultimately, incorporation of myosin inhibitors into cardiac amyloidosis treatment algorithms will depend on forthcoming randomized trials and real-world effectiveness data.